Since introducing its summer workshop, COVID-19: Current Pharmaceutical Developments for Cures and Preventions (now available on demand), AAPS has made sharing the latest science on COVID-19 a priority.
The conversation will continue at PharmSci 360, when scientists come together to share the latest on antiviral therapies and preventive immunizations. Registrants can dive into sessions on trial design, modeling, and regulatory perspectives.
Take a moment to understand the rapidly changing landscape of COVID-19 and related coronavirus research, as seen through the eyes of PharmSci 306’s closing plenary speakers:
-
Gregory Poland, M.D., MACP, FIDSA, FRCP, of the Mayo Clinic and Foundation, will discuss vaccine research.
- Rolf Hilgenfeld, Ph.D., of the University of Lubeck, Germany, will focus on antiviral drug development. See his latest paper in Science, “Crystal Structure of SARS-CoV-2 Main Protease Provides A Basis For Design of Improved a-Ketoamide Inhibitors.”
PharmSci 360 will present 350 session as well as hundreds of posters. Register now!